Ovid Therapeutics (OVID) Capital Expenditures Growth (1y) (2017 - 2024)
Powered by 
Analysis
Ovid Therapeutics (OVID) Capital Expenditures Growth (1y) (2017 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 26.65% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 19.70% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 16.88% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 3.02% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -13.75% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | -37.81% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | -34.92% |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -100.00% |
| Jun 30, 2024 | 1.04% |
| Mar 31, 2024 | 35.71% |
| Dec 31, 2023 | -110.84% |
| Jun 30, 2023 | -90.77% |
| Mar 31, 2023 | -69.52% |
| Dec 31, 2022 | -25.94% |
| Sep 30, 2022 | 76.55% |
| Jun 30, 2022 | 103,990,400.00% |
| Mar 31, 2022 | 298.95% |
| Dec 31, 2021 | 233.26% |
| Sep 30, 2021 | -54.20% |
| Jun 30, 2021 | -99.97% |
| Mar 31, 2021 | -93.90% |
| Dec 31, 2020 | -69.81% |
| Sep 30, 2020 | 26.30% |
| Jun 30, 2020 | -1.64% |
| Mar 31, 2020 | 3,961.12% |
| Dec 31, 2019 | 495.07% |
| Sep 30, 2019 | -84.48% |